Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
INGELHEIM, Germany & INDIANAPOLIS -- (BUSINESS WIRE) -- The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational t......
